An educational reference on peptides and compounds referenced in scientific research — organized by area of interest, not by product. Every entry distinguishes preclinical findings from clinical evidence and FDA status.
Peptides and analogs studied for their effects on appetite, glucose regulation, and body-weight pathways.
A triple hormone-receptor agonist in Phase 3 clinical trials for obesity and related metabolic conditions.
READ THE RESEARCH →A dual GLP-1/GIP receptor agonist, FDA-approved under specific brand names for type 2 diabetes and chronic weight management.
READ THE RESEARCH →A long-acting amylin analog studied in combination with GLP-1 therapies for weight management.
READ THE RESEARCH →Peptides studied in preclinical models for tissue repair and recovery-related pathways.
A synthetic peptide fragment studied in preclinical models for gut and tissue-healing pathways.
READ THE RESEARCH →A synthetic peptide related to thymosin beta-4, studied in preclinical models of tissue repair.
READ THE RESEARCH →A blend combining BPC-157 and TB-500, two peptides studied separately in preclinical tissue-repair research.
READ THE RESEARCH →Compounds studied for roles in cellular energy metabolism and mitochondrial function.
A mitochondrial-derived peptide studied for its role in cellular energy metabolism.
READ THE RESEARCH →A naturally occurring coenzyme central to cellular energy metabolism, studied in the context of aging and metabolic health.
READ THE RESEARCH →Copper peptides and related compounds studied in dermatological and tissue-remodeling research.
A naturally occurring copper peptide studied in dermatological and tissue-remodeling research.
READ THE RESEARCH →A copper tripeptide structurally related to GHK-Cu, studied in early cosmetic and dermatological research.
Needs formulation info READ THE RESEARCH →A tripeptide fragment of alpha-MSH studied preclinically for anti-inflammatory signaling.
READ THE RESEARCH →A blend combining KPV, GHK-Cu, BPC-157, and TB-500 — four peptides each studied separately in preclinical research.
READ THE RESEARCH →Peptides studied for effects on growth-hormone signaling, stress response, and cognitive pathways.
A selective growth-hormone secretagogue studied for its effects on growth hormone release.
READ THE RESEARCH →A combination of a GHRH analog (CJC-1295) and a growth-hormone secretagogue (ipamorelin), studied together for additive effects on growth hormone release.
READ THE RESEARCH →A GHRH analog FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-associated lipodystrophy.
READ THE RESEARCH →A synthetic peptide developed in Russia and studied there for anxiolytic and nootropic effects; not FDA-approved.
READ THE RESEARCH →A synthetic peptide developed in Russia and studied there for cognitive and neuroprotective effects; not FDA-approved.
READ THE RESEARCH →Peptides studied for roles in sexual function and reproductive hormone signaling.
A melanocortin receptor agonist FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women.
READ THE RESEARCH →A naturally occurring hormone studied for its central role in regulating reproductive hormone signaling.
READ THE RESEARCH →Common laboratory and compounding adjuncts referenced in research contexts.
An essential vitamin available both as an FDA-regulated prescription injectable for diagnosed deficiency and as an over-the-counter dietary supplement.
READ THE RESEARCH →A name commonly used for injectable lipotropic-nutrient blends; formulations vary and are not FDA-approved as weight-loss drugs.
READ THE RESEARCH →Sterile water containing a small amount of benzyl alcohol, FDA-regulated as a multi-dose diluent for pharmaceutical and laboratory reconstitution.
READ THE RESEARCH →